Trial Profile

Low-dose CDB 4124 (at doses of 1, 3, 6, 9 and 12mg) for the treatment of uterine leiomyoma and endometriosis

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 01 Apr 2014

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Telapristone (Primary)
Indications Endometriosis; Uterine leiomyoma
Focus Adverse reactions
Sponsors Repros Therapeutics

Most Recent Events

17 Dec 2010 Planned number of patients changed to 60. According to a Repros Therapeutics media release, there will be 12 patients per dose cohort.
17 Dec 2010 Status changed from not yet recruiting to recruiting. According to a Repros media release, patients in the 1mg dose cohort have completed 8 weeks of treatment, and dosing of the 3mg dose cohort will commence soon.
27 Jul 2010 The Investigational Review Board approved the trial. Dosing of the first patient expected in the quarter 3 of 2010.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com